Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay Herson

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
International Journal of Clinical Oncology|July 22, 2015
Strategies for dealing with fraud in clinical trialsJay Herson
Contemporary Clinical Trials|January 30, 2021
Clinical trial preparations for the next pandemicJay Herson
Cardio-Oncology (London, England)|July 19, 2022
Cardiovascular adverse events in oncology trials: understanding and appreciating the differences between clinical trial data and real-world reportsMichael S Ewer, Jay Herson
Cardio-Oncology (London, England)|February 27, 2025
Is the pendulum slowly starting to swing back?Michael S Ewer, Jay Herson
The Journal of Pharmacology and Experimental Therapeutics|April 27, 2023
Cardiac Monitoring Guidelines in Clinical Trials and Post-Approval Surveillance for Patients Exposed to Anticancer Treatments: Do the Data Support the Recommendations?Michael S Ewer, Nicolas L Palaskas, Jay Herson
Cardio-Oncology (London, England)|March 19, 2026
Clinical added value of triplicate electrocardiograms: a review of 505 triplicate setsMichael S Ewer, Hyeon-Ju Ryo Ali, Nicolas L Palaskas, et al.
Therapeutic Innovation & Regulatory Science|January 8, 2024
Aggregate IND Safety Reporting for Smaller Companies and ProgramsGreg Ball, Mengchun Li, Jim Buchanan, et al.
Clinical Trials (London, England)|August 10, 2006
Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees, Dennis O Dixon, Ralph S Freedman, et al.
Breast (Edinburgh, Scotland)|April 23, 2021
Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trialHope S Rugo, Eduardo J Pennella, Unmesh Gopalakrishnan, et al.
JAMA|December 6, 2016
Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical TrialHope S Rugo, Abhijit Barve, Cornelius F Waller, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
International Journal of Clinical Oncology|July 22, 2015
Strategies for dealing with fraud in clinical trialsJay Herson
Contemporary Clinical Trials|January 30, 2021
Clinical trial preparations for the next pandemicJay Herson
Cardio-Oncology (London, England)|July 19, 2022
Cardiovascular adverse events in oncology trials: understanding and appreciating the differences between clinical trial data and real-world reportsMichael S Ewer, Jay Herson
Cardio-Oncology (London, England)|February 27, 2025
Is the pendulum slowly starting to swing back?Michael S Ewer, Jay Herson
The Journal of Pharmacology and Experimental Therapeutics|April 27, 2023
Cardiac Monitoring Guidelines in Clinical Trials and Post-Approval Surveillance for Patients Exposed to Anticancer Treatments: Do the Data Support the Recommendations?Michael S Ewer, Nicolas L Palaskas, Jay Herson
Cardio-Oncology (London, England)|March 19, 2026
Clinical added value of triplicate electrocardiograms: a review of 505 triplicate setsMichael S Ewer, Hyeon-Ju Ryo Ali, Nicolas L Palaskas, et al.
Therapeutic Innovation & Regulatory Science|January 8, 2024
Aggregate IND Safety Reporting for Smaller Companies and ProgramsGreg Ball, Mengchun Li, Jim Buchanan, et al.
Clinical Trials (London, England)|August 10, 2006
Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees, Dennis O Dixon, Ralph S Freedman, et al.
Breast (Edinburgh, Scotland)|April 23, 2021
Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trialHope S Rugo, Eduardo J Pennella, Unmesh Gopalakrishnan, et al.
JAMA|December 6, 2016
Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical TrialHope S Rugo, Abhijit Barve, Cornelius F Waller, et al.
Pageof 2